-
Since December 20, the online price of a large number of drugs in the area has been reduced, with a maximum reduction of 3,162 yuan
Time of Update: 2022-12-30
Recently, the website information of the Hubei Provincial Medical Security Bureau shows that the bureau has reviewed and publicized some drugs that voluntarily applied for a reduction in the online price in November 2022, and a total of 22 online drugs have been adjusted to the online price, involving 21 generic names of 20 enterprises.
-
【Cell】Fight pancreatic cancer! Yang Caiguang's team at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, discovered a ClpP agonist
Time of Update: 2022-10-03
High-throughput screening combined with synthetic optimization to obtain a new skeleton of ClpP agonist ZG111, activated ClpP proteolytic enzyme function in pancreatic cancer cells of different KRAS genotypes, intervened in mitochondrial respiratory chain complex homeostasis, and indirectly inhibited the proliferation of OXPHOS function anti-pancreatic cancer cells.
-
Courier! Eli Lilly PD-1 agonist is clinically declared in China
Time of Update: 2022-09-30
A monoclonal antibody that binds to and excites the PD-1 receptor, with the potential to become a "first-in-class" therapy, has completed a Phase 2 clinical trial overseas for the treatment of rheumatoid arthritis Screenshot source: CDE official website The PD-1 target has played an extremely important role in tumor treatment.
-
npj Parkinsons Dis: What inspires us about Parkinsons morbidity, prevalence and mortality across Norway
Time of Update: 2022-04-24
In the current study, Brage Brakedal lamps at Haukeland University Hospital, Norway, used the Norwegian Drug Prescription Database (NorPD) to assess the incidence, prevalence and mortality of PD in the entire Norwegian population between 2004 and 2017 .
-
Lipid-lowering drug introduced by Eddingpharm was approved in Hong Kong, China
Time of Update: 2022-04-20
On March 29, Eddingpharm announced that the new drug marketing application of Eicosapentaenoic acid ethyl ester capsules (trade name Vascepa) for reducing the risk of cardiovascular events has been approved in Hong Kong, China.
-
Express treatment of autoimmune diseases, bifunctional antibodies show a new mode of suppressing immune response
Time of Update: 2021-12-05
Obexelimab is a new type of bifunctional antibody that simultaneously targets FcγRIIb that inhibits B cell activity and CD19 antigen expressed by B cells for the treatment of autoimmune diseases .
-
Pfizer's new crown oral drug Paxlovid is $529 per course of treatment
Time of Update: 2021-12-05
On October 27th, Merck and its partner Ridgeback announced that they had reached a treatment license agreement with the United Nations to give up patents in 105 low- and middle-income countries around the world to allow them to produce generic drugs .
-
The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O-drug of Kaixing Pharmaceutical was approved
Time of Update: 2021-10-21
On October 11, Kaifeng Pharmaceutical announced that the clinical trial of ALK-1 monoclonal antibody (GT90001C) combined with Nivolumab has been approved by the China National Medical Products Administration on October 9 for use in advanced hepatocytes without systemic treatment.
-
The Comprehensive Department of the State Food and Drug Administration solicits comments on the revised draft of the "Catalogue of Class I Medical Devices
Time of Update: 2021-08-26
On August 18, the Comprehensive Department of the State Food and Drug Administration issued a public solicitation of comments on the revised "Catalogue of Class I Medical Devices" (draft for comments) .
-
VistaGen's new oral NMDA-agent antagonist AV-101 has won the FDA's second fast-track status
Time of Update: 2021-02-14
Recently, the company announced that the U.S. Food and Drug Administration (FDA) has granted the experimental drug AV-101 as a non-opioid non-sedative for the treatment of neuropathic pain fast-track status.
-
Policy support plus-size gene testing Cell immunotherapy enjoys dividends
Time of Update: 2021-02-06
In 2017, genetic sequencing giant Illumina caused a number of movements. From January 9th to 13th, Illumina unveiled NovaSeq, a next-generation sequencing system, at this year's JPMorgan Health Confer
-
Alsophila
Time of Update: 2020-11-06
Only at the top of the tree are many large, long plume-shaped compound leaves that stretch around.
spores mature and disperse with the wind and fall into the soil, first germinated into a heart-shaped green flat primary leaf, which can be photocheditored.
-
Innovent's Class 1 new drug IBI112 starts Phase I clinical trial
Time of Update: 2020-09-04
secondary purpose was to evaluate the characteristics and immunogenicity of post-drug pharmacological dynamics (PK) of IBI112 in a single dose of subderfic injection or intravenous giving to healthy subjects in China.
purpose of the study was to evaluate the post-IBI112 pharmacodynamic (PD) characteristics of single-dose subderfect injections or intravenous giving to healthy subjects in China.
-
FDA approves first new treatment for rare adrenal tumors
Time of Update: 2020-08-14
But patients still lack effective systemic therapies for symptoms such as tumor-related hypertension, and now they have an approved treatment that can be used to lower their blood pressure and reduce the size of tumors in some patients.
-
Roche PI3K alpha inhibitors were declared clinically and accepted for the first time in China
Time of Update: 2020-07-24
The Latest announcement from the Drug Review Center (CDE) of the State Drug Administration of China shows that Roche has declared clinical trials in China and received acceptance of the new drug PI3K
